APO-DOXYCYCLINE MODIFIED RELEASE 40 MG
DOXYCYCLINE (DOXYCYCLINE MONOHYDRATE) : 40 MG · DIN 02495538 · APOTEX INC
Health Canada status: APPROVED
What is APO-DOXYCYCLINE MODIFIED RELEASE?
APO-DOXYCYCLINE MODIFIED RELEASE 40 MG contains DOXYCYCLINE (DOXYCYCLINE MONOHYDRATE) : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02495538, held by APOTEX INC, supplied as CAPSULE (IMMEDIATE AND EXTENDED RELEASE) for ORAL administration. Health Canada currently lists it as approved, status dated 13-Mar-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02495538 |
|---|---|
| Brand name | APO-DOXYCYCLINE MODIFIED RELEASE |
| Generic / active ingredient | DOXYCYCLINE (DOXYCYCLINE MONOHYDRATE) : 40 MG |
| Manufacturer | APOTEX INC |
| Strength | 40 MG |
| Dosage form | CAPSULE (IMMEDIATE AND EXTENDED RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01AA02 DOXYCYCLINE |
| AHFS class | 84:04.04 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 13-Mar-2024 |
What can be used instead?
Other Canadian products sharing ATC code J01AA02 DOXYCYCLINE. 14 of 43 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-DOXYCYCLINE | 100 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02556928 |
| APO-DOXY CAP 100MG | 100 MG | CAPSULE | APOTEX INC | MARKETED | DIN 00740713 |
| APO-DOXY TABS 100MG | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 00874256 |
| APO-DOXYCYCLINE MR | 40 MG | CAPSULE (IMMEDIATE AND DELAYED RELEASE) | APOTEX INC | MARKETED | DIN 02512645 |
| APPRILON | 40 MG | CAPSULE (IMMEDIATE AND DELAYED RELEASE) | GALDERMA CANADA INC | MARKETED | DIN 02375885 |
| DOXYCIN TAB 100MG | 100 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 00860751 |
| DOXYTAB | 100 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 00887064 |
| JAMP DOXYCYCLINE CAPSULES | 100 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02528940 |
| JAMP DOXYCYCLINE TABLETS | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02554372 |
| M-DOXYCYCLINE | 100 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02543478 |
Who else supplies DOXYCYCLINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DOXYCYCLINE appears in 306 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.